Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
Completed · Phase 4
Conditions studied: SARS-CoV Infection
In brief
The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical ventilation in subjects with mild to moderate hypoxia due to the corona virus that causes COVID-19. Based on previous animal studies, the researchers hypothesize that the addition of an ARB is beneficial in abating acute lung injury in subjects in early stages of SARS-CoV-2 viral induced hypoxia.
Key facts
- Study ID
- NCT04340557
- Run by
- Sharp HealthCare
- People needed
- 31
- Starts
- 2020-03-27
- Expected to finish
- 2020-06-13
- Last updated by the study team
- 2021-05-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Confirmed COVID-19 positive test result
- Mild to moderate respiratory symptoms of COVID-19.
- Systolic blood pressure ≥ 105 mmHg.
- Screen within 3 days of a positive COVID-19 test.
- Age ≥18 years old.
- Access to a phone in the hospital room or an electronic device that is capable of receiving phone or video calls.
- Able to read/write/speak English or Spanish fluently.
- Subjects must have the capacity to provide consent or an appropriate LAR to provide informed consent.
- Negative pregnancy test for women of childbearing potential and subject is randomized to the study arm.
You may not qualify if…
- Severe allergy to any ARB or ACE-inhibitor, including angioedema
- In the intensive care unit at screening.
- Home meds include any kind of ACE inhibitor or ARB
- Acute Kidney Injury (50% reduction in GFR from baseline at admission to any time during treatment in the study treatment arm)
- Hyperkalemia >5.0 mmol/L at baseline or any time during treatment in the study treatment arm
- Creatinine Clearance < 30 ml/min at baseline or any time during treatment in the study treatment arm
Where it is running
- Sharp Grossmont Hospital — La Mesa, California, United States
- Sharp Chula Vista Medical Center — San Diego, California, United States
- Sharp Memorial Hospital — San Diego, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.